Experienced and Highly Focused Management Team

The XORTX team of multi-disciplinary industry professionals is capable of drug development from discovery to marketing approval. Over 60 years of manufacturing, clinical and regulatory drug development experience.

Concept Validating Clinical Trials

Recent human studies have defined a role for chronically increased serum uric acid (SUA) in a disease axis that includes rare-”orphan” diseases, such as autosomal dominant polycystic kidney disease, hereditary hypouricemia, blood pressure, kidney injury, diabetes, and diabetic nephropathy. Stll more recent human studies have shown that decreasing and maintaining lower uric acid levels using..More

Cornerstone Intellectual Property

XORTX Patents and patent applications claim the use of and composition of uric acid lowering agents for the treatment of hypertension, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy and other diseases.

Latest Press Releases

XORTX Announces PKD Foundation Collaboration

CALGARY, AB – April 19, 2018 – XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX) is pleased to announce that the...

XORTX Announces Issuance of Stock Options

CALGARY, AB – March 20, 2018 – XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX), a biopharmaceutical company focused on developing...

XORTX Therapeutics Provides Corporate Update

CALGARY, AB – February 27, 2018 – XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX), a biopharmaceutical company focused on developing...